Logo

Clover Initiates P-II Trial of COVID-19 Vaccine as Heterologous Booster for the Treatment of COVID-19

Share this

Clover Initiates P-II Trial of COVID-19 Vaccine as Heterologous Booster for the Treatment of COVID-19

Shots:

  • The company initiates a P-II trial in 2 stages to evaluate 3 formulations, immunogenicity &  safety of SCB-2019 as a heterologous booster dose in 520 patients with COVID-19 prior vaccinated with CoronaVac or recombinant COVID-19 vaccine at multiple sites in Brazil. The trial is sponsored by IDOR & funded by Bill & Melinda Gates Foundation
  • The objective is to determine the optimal vaccine formulation over the homologous booster of a recombinant COVID-19 vaccine. The results are expected in H1’22
  • The SPECTRA trial data was reported in Sep 2021 showed that SCB-2019 showed a strong boosting effect on neutralizing Ab titers, favorable safety profile to support COVID-19 vaccine  as a booster vaccine

 Ref: Globenewswire | Image: Clover

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions